4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
10.07
-0.31 (-2.99%)
Jul 24, 2026, 4:00 PM EDT - Market closed
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, 4D Molecular Therapeutics stock has a consensus rating of "Buy" and an average price target of $28.22. The average 1-year stock price forecast is 180.24% higher than the current stock price, while the lowest is $17 (+68.82%) and the highest is $36 (+257.50%).
Price Target: $28.22 (+180.24%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 30, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $36 | Buy | Reiterates | $36 | +257.50% | Jun 30, 2026 |
| Chardan Capital | Chardan Capital | Buy Reiterates $26 | Buy | Reiterates | $26 | +158.19% | May 8, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $35 | Buy | Maintains | $35 | +247.57% | May 8, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $38 → $33 | Buy | Maintains | $38 → $33 | +227.71% | May 8, 2026 |
Financial Forecast
Revenue This Year
11.60M
from 85.21M
Decreased by -86.39%
Revenue Next Year
17.51M
from 11.60M
Increased by 50.93%
EPS This Year
-3.93
from -2.42
EPS Next Year
-3.77
from -3.93
EPS and Forward PE are based on non-GAAP adjusted numbers.